Skip to main content
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2023 Sep 5;16:723–724. doi: 10.2147/OTT.S437997

microRNA-130a is an Oncomir Suppressing the Expression of CRMP4 in Gastric Cancer [Retraction]

PMCID: PMC10492565  PMID: 37694104

Zhou Y, Li R, Yu H, Wang R, Shen Z. Onco Targets Ther. 2017;10:3893-3905.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from Figures 2, 4 and 5 with images from unrelated articles. Specifically,

  • The western blot images for Figure 2D, CRMP4 and GAPDH, have been duplicated with the images for Figure 4B, CTHRC1 and GAPDH, respectively, from Lai Yh, Chen J, Wang Xp, et al. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer. J Exp Clin Cancer Res. 2017;36:92. https://doi.org/10.1186/s13046-017-0564-7.

  • The image for Figure 4B, Cell invasion, NC, has been duplicated with the image for Figure 6D, Cell invasion, BGC823-shNC from Guo H, Xia B. Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer. BMC Cancer. 2016;16:565. https://doi.org/10.1186/s12885-016-2593-6.

  • The image for Figure 5D, BGC823, has been duplicated with the image for Figure 1c, CTHRC1, Carcinoma tissue, from Chen G, Wang D, Zhao X, et al. miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling. Cancer Cell Int. 2017;17:118. https://doi.org/10.1186/s12935-017-0469-8.

  • The images for Figure 6B, miR-130a + CRMP4-shRNA, have been duplicated.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As the findings could not be verified the Editor and Publisher made the decision to retract the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.


Articles from OncoTargets and Therapy are provided here courtesy of Dove Press

RESOURCES